We hypothesized that a combination of the current key plasma biomarkers Abeta42/40, P‐tau, GFAP, and NfL can aid in (early) AD, FTD, or DLB diagnosis and in differential diagnosis of AD versus FTD or DLB in the daily clinical dementia practice. This evidence concerns the gene MAPT and Lewy body dementia.